Short answer
Design Therapeutics, Inc. (DSGN) filed its Q1 2026 10-Q quarterly report on Apr 28, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $0 with net income of −$18M.
Q1 2026 key financials · XBRL
- Revenue
- $0
- Net income
- −$18M
- +0.4% YoY
- EPS (diluted)
- −$0.29
- +6.5% YoY
Source: XBRL data from the Design Therapeutics, Inc. (DSGN) Q1 2026 10-Q on SEC EDGAR. USD.
Design Therapeutics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No newly triggered risk identified; provided section contains carried-forward 10-K disclosures
- Liquidity risk: $222.8 million cash, equivalents and securities funds operations for more than 12 months but not regulatory approval
- Regulatory risk: FDA clinical hold on DT-216P2 lifted in December 2025 after notice received in June 2025
- Clinical risk: RESTORE-FA update on endogenous frataxin levels expected in the second half of 2026
- Financial-loss risk: net loss $17.6 million for three months ended March 31, 2026 vs $69.8 million for 2025
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Design Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.